GSK And Takeda Boost Arrowhead’s Coffers, But In-House Results Crucial To Gene Silencing Platform
Can RNAi Work In The Lung?
Executive Summary
Arrowhead is expecting a flurry of early-stage results from its in-house pipeline, including in lung diseases, where gene silencing platforms have so far struggled to reach, as it banks two recent milestone payments.
You may also be interested in...
Takeda Charges Into Diversification With ITP Win
The company announced positive topline results from a Phase II study of mezagitamab and expects to have five programs in Phase III development this fiscal year.
Arrowhead Eager To Take On ‘Straightforward’ NASH Approach Abandoned By J&J
J&J pipeline review results in return of PNPLA3-targeted NASH candidate optioned under 2018 alliance, but the fate of a hepatitis B candidate included in that deal is undetermined so far.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.